Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
J Bone Oncol ; 29: 100364, 2021 Aug.
Article in English | MEDLINE | ID: mdl-34150488

ABSTRACT

More than 35% of lung adenocarcinoma patients have bone metastases at diagnosis and have a poor survival. Periostin, a carboxylated matrix protein, mediates lung cancer cell dissemination by promoting epithelial-mesenchymal transition, and is involved in bone response to mechanical stress and bone formation regulation. This suggests that periostin may be used as a biomarker to predict survival in lung cancer patients. Serum periostin was assessed at diagnosis in a prospective cohort of 133 patients with lung adenocarcinoma of all stages. Patients were divided into localized and bone metastatic groups. Both groups were matched to healthy controls. Survival analysis and Cox proportional hazards models were conducted in the total population and in bone metastatic group. The median serum periostin level was higher in bone metastatic (n = 67; median: 1752 pmol/L) than in the localized group (n = 66; 861 pmol/L; p < 0.0001). Patients with high periostin (>median) had a poorer overall survival in the whole population (33.3 weeks vs. NR; p < 0.0001) and the bone metastatic group (24.4 vs. 66.1 weeks; p < 0.001). In multivariate analysis, patients with high periostin had increased risk of death (HR = 2.09, 95%CI [1.06-4.13]; p = 0.03). This was also found in the bone metastatic group (HR = 3.62, 95%CI [1.74-7.52]; p = 0.0005). Immunohistochemistry on bone metastasis biopsies showed periostin expression in the bone matrix and nuclear and cytoplasmic staining in cancer cells. Serum periostin was an independent survival biomarker in all-stage and in bone metastatic lung adenocarcinoma patients. IHC data suggest that periostin might be induced in cancer cells in bone metastatic niche in addition to bone microenvironment expression.

2.
Rev Mal Respir ; 37(4): 293-298, 2020 Apr.
Article in French | MEDLINE | ID: mdl-32273117

ABSTRACT

INTRODUCTION: Due to an increase in life expectancy, onco-pulmonologists and thoracic surgeons are more frequently faced with octogenarian patients with lung cancer. In this age group, treatment modalities may need to be revised because of the increasing presence of comorbidities. Surgery remains the reference treatment for early stage disease, but mortality rates and postoperative complications are higher in this group of patients. One of the solutions to reduce the operative risk would be to develop videoassisted thoracoscopic pulmonary resection surgery. The aim of this study was to evaluate the results of this form of lung cancer surgery in octogenarians. METHODS: All patients 80 years old or more who underwent videoassisted lung cancer surgery from 2014 to 2018 at Lyon University Hospital were included. Wedge resections and diagnostic procedures were excluded. RESULTS: Nineteen patients (13 men, 6 women) were included. The median age was 82 years old. All patients had undergone videoassisted lobectomy. Three patients required conversion to thoracotomy (15.8%). All patients underwent complete resection (R0). One patient had N1 lymph node involvement, all others were N0. The postoperative complication rate was 68.4%, the majority of which were grade II of the Clavien classification. Perioperative mortality was 5.3%. CONCLUSIONS: Videoassisted lung cancer resection in a selected population of octogenarians is associated with satisfactory short-term results. It is reasonable to favour minimally invasive techniques in this population, even if the proof of their superiority has not yet been firmly established.


Subject(s)
Carcinoma, Non-Small-Cell Lung/surgery , Lung Neoplasms/surgery , Postoperative Complications/epidemiology , Postoperative Complications/mortality , Thoracic Surgery, Video-Assisted , Age of Onset , Aged, 80 and over , Carcinoma, Non-Small-Cell Lung/epidemiology , Carcinoma, Non-Small-Cell Lung/mortality , Female , France/epidemiology , Hospital Mortality , Humans , Lung Neoplasms/epidemiology , Lung Neoplasms/mortality , Male , Morbidity , Mortality , Pneumonectomy/adverse effects , Pneumonectomy/mortality , Pneumonectomy/statistics & numerical data , Postoperative Complications/etiology , Retrospective Studies , Thoracic Surgery, Video-Assisted/adverse effects , Thoracic Surgery, Video-Assisted/mortality , Thoracic Surgery, Video-Assisted/statistics & numerical data , Thoracotomy/adverse effects , Thoracotomy/mortality , Thoracotomy/statistics & numerical data
3.
Gen Thorac Cardiovasc Surg ; 67(3): 321-323, 2019 Mar.
Article in English | MEDLINE | ID: mdl-29492835

ABSTRACT

A 75 year old man presented with left upper lobe squamous cell carcinoma. Severe aortic stenosis has been discovered during preoperative assessment. In this situation, two therapeutic strategies are described: concomitant or two-staged procedures. The debate has not yet led to the conclusion on whether preferably performing one or the other. Furthermore, in an oncologic context, using cardiopulmonary bypass is still controversial. So, thoracic and cardiac surgeons jointly proposed to the patient a transcatheter aortic valve implantation followed, 72 h later, by lung cancer resection. This case report describes a way to treat both diseases avoiding cardiopulmonary bypass adverse effects and without delaying lung cancer treatment.


Subject(s)
Aortic Valve Stenosis/surgery , Carcinoma, Squamous Cell , Lung Neoplasms , Aged , Aortic Valve Stenosis/complications , Humans , Male , Transcatheter Aortic Valve Replacement/methods
4.
Rev Pneumol Clin ; 72(1): 3-9, 2016 Feb.
Article in French | MEDLINE | ID: mdl-26725006

ABSTRACT

INTRODUCTION: This retrospective study was undertaken to evaluate late results of lung cancer surgery in octogenerians. METHODS: All patients 80years old or more who underwent a lung resection for cancer from 2000 to 2010 at Lyon University Hospital were included. No patients were treated with video-assisted surgery. Wedge resections were excluded. RESULTS: Sixty-three patients (42 men, 21 women) were operated. The median age was 82years. Operative mortality was 4.7%. The rate of perioperative complications was 49%. The late survival was 34% at 5years. Five-year survival by nodal involvement was N0, 36%; N1, 29%; N2 20%, P<0.05. Patients with a squamous cell carcinoma (24) had a better long-term survival than patients with an adenocarcinoma (30), 33% and 25% respectively at 5years, P<0.05. The rate of recurrence was 33.9%. CONCLUSIONS: Surgical treatment of lung cancer in selected population of octogenerians is associated with satisfactory early and long-term results. Survival is influenced by nodal involvement and by the pathologic type of the cancer.


Subject(s)
Aged , Lung Neoplasms/surgery , Aged, 80 and over , Female , Geriatric Assessment , Humans , Lung Neoplasms/diagnosis , Lung Neoplasms/epidemiology , Male , Pneumonectomy/methods , Pneumonectomy/mortality , Pneumonectomy/statistics & numerical data , Postoperative Complications/epidemiology , Retrospective Studies , Survival Analysis , Treatment Outcome
5.
Rev Pneumol Clin ; 72(1): 101-7, 2016 Feb.
Article in French | MEDLINE | ID: mdl-26209034

ABSTRACT

Graft-versus-host disease (GVHD) is a classic and frequent multisystemic complication of bone marrow allografts. It has also been reported after the transplantation of solid organs such as the liver or gut. Recent cases of GVHD have been reported after lung and heart-lung transplant. Skin, liver, gastrointestinal tract and bone marrow are the organ preferentially affected by GVHD. Corticosteroid is the first line treatment of GVHD. The prognosis reported in solid organ transplants is poor with infectious complications favoured by immunosuppressive therapy. In this article, we report a case of a patient with cystic fibrosis who presented a probable GVHD 18 months after a lung transplant and a literature review of similar cases.


Subject(s)
Cystic Fibrosis/therapy , Graft vs Host Disease/pathology , Lung Transplantation/adverse effects , Adult , Female , Humans , Respiratory Insufficiency/etiology , Respiratory Insufficiency/therapy
6.
Rev Pneumol Clin ; 72(1): 87-94, 2016 Feb.
Article in French | MEDLINE | ID: mdl-25727653

ABSTRACT

Lung transplantation (LT) is now considered as an excellent treatment option for selected patients with end-stage pulmonary diseases, such as COPD, cystic fibrosis, idiopathic pulmonary fibrosis, and pulmonary arterial hypertension. The 2 goals of LT are to provide a survival benefit and to improve quality of life. The 3-step decision process leading to LT is discussed in this review. The first step is the selection of candidates, which requires a careful examination in order to check absolute and relative contraindications. The second step is the timing of listing for LT; it requires the knowledge of disease-specific prognostic factors available in international guidelines, and discussed in this paper. The third step is the choice of procedure: indications of heart-lung, single-lung, and bilateral-lung transplantation are described. In conclusion, this document provides guidelines to help pulmonologists in the referral and selection processes of candidates for transplantation in order to optimize the outcome of LT.


Subject(s)
Lung Transplantation/methods , Lung Transplantation/statistics & numerical data , Patient Selection , Choice Behavior , Contraindications , Cystic Fibrosis/therapy , Humans , Idiopathic Pulmonary Fibrosis/therapy , Lung Transplantation/standards , Pulmonary Disease, Chronic Obstructive/therapy , Respiratory Insufficiency/therapy , Time Factors , Waiting Lists
7.
Clin Microbiol Infect ; 21(5): 472.e7-10, 2015 May.
Article in English | MEDLINE | ID: mdl-25708551

ABSTRACT

Multidrug-resistant (MDR) tuberculosis (TB) is an emerging concern in communities with a low TB prevalence and a high standard of public health. Twenty-three consecutive adult MDR TB patients who were treated at our institution between 2007 and 2013 were reviewed for demographic characteristics and anti-TB treatment management, which included surgical procedures and long-term patient follow-up. This report of our experience emphasizes the need for an individualized approach as MDR TB brings mycobacterial disease management to a higher level of expertise, and for a balance to be found between international current guidelines and patient-tailored treatment strategies.


Subject(s)
Case Management/organization & administration , Communicable Diseases, Emerging/diagnosis , Communicable Diseases, Emerging/drug therapy , Tuberculosis, Multidrug-Resistant/diagnosis , Tuberculosis, Multidrug-Resistant/therapy , Adult , Antitubercular Agents/therapeutic use , Communicable Diseases, Emerging/epidemiology , Female , Humans , Male , Precision Medicine/methods , Prevalence , Retrospective Studies , Surgical Procedures, Operative , Tuberculosis, Multidrug-Resistant/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...